Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease (Q35123163)

6 August 2017

title

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease (English)

1 reference

6 August 2017

Carin M van Gelder

1

1 reference

6 August 2017

Marianne Hoogeveen-Westerveld

2

1 reference

6 August 2017

Marian A Kroos

3

1 reference

6 August 2017

Iris Plug

4

1 reference

6 August 2017

Ans T van der Ploeg

5

1 reference

6 August 2017

Arnold J J Reuser

6

1 reference

6 August 2017

publication date

9 April 2014

1 reference

Journal of Inherited Metabolic Disease

6 August 2017

published in

1 reference

6 August 2017

volume

38

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

305-314

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-014-9707-6

6 August 2017

exact match

0 references

cites work

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

The impact of antibodies in late-onset Pompe disease: a case series and literature review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Atypical immunologic response in a patient with CRIM-negative Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

A randomized study of alglucosidase alfa in late-onset Pompe's disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

The danger model: a renewed sense of self

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Elimination of antibodies to recombinant enzyme in Pompe's disease.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Left ventricular mass in 169 healthy children and young adults assessed by three-dimensional echocardiography.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

A novel acid alpha-glucosidase mutation identified in a Pakistani family with glycogen storage disease type II.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4341007

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

27 September 2018

1 reference

12 December 2020

How to describe the clinical spectrum in Pompe disease?

1 reference

12 December 2020

Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype

1 reference

12 December 2020

Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry

1 reference

12 December 2020

Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study

1 reference

12 December 2020

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

12 December 2020

10.1007/S10545-014-9707-6

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference